AtriCure (NASDAQ:ATRC) Posts Earnings Results, Beats Expectations By $0.11 EPS

AtriCure (NASDAQ:ATRC - Get Free Report) released its quarterly earnings results on Tuesday. The medical device company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.11, Zacks reports. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The business had revenue of $123.62 million for the quarter, compared to analyst estimates of $122.92 million. During the same period last year, the firm earned ($0.28) earnings per share. AtriCure's revenue for the quarter was up 13.5% compared to the same quarter last year. AtriCure updated its FY 2025 guidance to -0.550--0.500 EPS.

AtriCure Trading Up 2.5 %

AtriCure stock traded up $0.73 during trading hours on Friday, hitting $30.02. The stock had a trading volume of 855,143 shares, compared to its average volume of 654,587. The business's 50 day simple moving average is $33.57 and its 200-day simple moving average is $34.72. AtriCure has a one year low of $18.94 and a one year high of $43.11. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -31.60 and a beta of 1.65. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13.

Analysts Set New Price Targets

Several brokerages have weighed in on ATRC. JMP Securities reaffirmed a "market outperform" rating and issued a $60.00 price objective on shares of AtriCure in a report on Wednesday. Needham & Company LLC reduced their price objective on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Wednesday. UBS Group dropped their target price on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research report on Wednesday. Piper Sandler increased their price target on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Finally, Canaccord Genuity Group cut their target price on AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.67.

Insider Activity

In other news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the transaction, the director now owns 17,828 shares in the company, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.50% of the stock is currently owned by insiders.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.